This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Results of an Open, Pilot Trial

Clark C. Otley, MD; Marc R. Avram, MD; Richard A. Johnson, MD

Arch Dermatol. 1995;131(9):1047-1050.

Abstract
Background
Human immunodeficiency virus-associated eosinophilic folliculitis is a pruritic eruption seen in advanced infection with human immunodeficiency virus. The associated pruritus causes considerable morbidity and is poorly responsive to conventional therapy. We studied whether isotretinoin would prove efficacious in the treatment of human immunodeficiency virus-associated eosinophilic folliculitis. Seven patients with biopsy specimen-proved human immunodeficiency virus-associated eosinophilic folliculitis were treated with a mean of 7.7 weeks of isotretinoin therapy and their responses were monitored.

Observations
All patients responded with complete symptomatologic and clinical remission within 1 to 4 weeks of isotretinoin therapy. Four (57%) of seven patients remained in complete remission after just one course of isotretinoin therapy, while three (43%) of seven patients experienced up to three brief relapses, all rapidly responsive to further isotretinoin therapy. Patients remained free of disease for up to 9 months after therapy.

Conclusions
Isotretinoin appears to be a promising treatment for human immunodeficiency virus-associated eosinophilic folliculitis. A double-blind, placebo-controlled trial is indicated.

(Arch Dermatol. 1995;131:1047-1050)

Author Affiliations
From the Department of Dermatology, Harvard Medical School, and Division of Dermatology, New England Deaconess Hospital, Boston, Mass. Dr Avram is now with the Stough Clinic, Hot Springs, Ark.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Topical Tacrolimus for Effective Treatment of Eosinophilic Folliculitis Associated With Human Immunodeficiency Virus Infection
Toutous-Trellu et al.
Arch Dermatol 2005;141:1203-1208.
FULL TEXT  

Eosinophilic Folliculitis: Before and After the Introduction of Antiretroviral Therapy
Rajendran et al.
Arch Dermatol 2005;141:1227-1231.
ABSTRACT | FULL TEXT  

Eosinophilic Folliculitis in 2 HIV-Positive Women
Arch Dermatol 2004;140:463-465.
 

Contraceptive Efficacy
Trussell
Arch Dermatol 1995;131:1064-1068.
ABSTRACT